Literature DB >> 10674872

The pure antiestrogen ICI 182780 is more effective in the induction of apoptosis and down regulation of BCL-2 than tamoxifen in MCF-7 cells.

P Diel1, K Smolnikar, H Michna.   

Abstract

There is increasing evidence that induction of apoptosis by antihormones is an important mechanism in regard to their growth inhibitory action on hormone dependent tumors. In this report we have compared the efficiency of tamoxifen (Tam) and the pure antiestrogen ICI 182780 (ZM) to induce apoptosis in the estrogen dependent breast cancer cell line MCF-7. Clear evidence for induction of apoptosis could be demonstrated after treatment with both antiestrogens. Application of the pure antiestrogen ZM led to a significantly higher induction of apoptosis compared to the partial agonistic compound Tam. The ability of the two compounds to induce apoptosis correlated with their growth inhibitory action. On the molecular level administration of ZM led to a time dependent steady decrease of BCL-2 mRNA and protein. Administration of Tam also initially decreased the expression of BCL-2. In contrast to ZM treatment, BCL-2 expression increased again after 8 h of incubation with Tam. After 96 h Tam treated cells expressed BCL-2 levels nearly as high as untreated cells. In general, ZM decreased BCL-2 levels more effectively than Tam. Our results demonstrate that ZM and Tam possess quantitative and qualitative differences in their ability to down regulate BCL-2 expression. The higher ability of the pure antiestrogen to down regulate BCL-2 expression may explain the superiority of the pure antiestrogen to induce apoptosis and to inhibit the growth of MCF-7 cells.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10674872     DOI: 10.1023/a:1006338123126

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  19 in total

1.  The HER4/4ICD estrogen receptor coactivator and BH3-only protein is an effector of tamoxifen-induced apoptosis.

Authors:  Anjali Naresh; Ann D Thor; Susan M Edgerton; Kathleen C Torkko; Rakesh Kumar; Frank E Jones
Journal:  Cancer Res       Date:  2008-08-01       Impact factor: 12.701

2.  An integrated microfluidic cell array for apoptosis and proliferation analysis induction of breast cancer cells.

Authors:  Huixue Song; Tan Chen; Baoyue Zhang; Yifan Ma; Zhanhui Wang
Journal:  Biomicrofluidics       Date:  2010-10-08       Impact factor: 2.800

3.  Estrogen enhances the efficacy of an oncolytic HSV-1 mutant in the treatment of estrogen receptor-positive breast cancer.

Authors:  Brendon M Stiles; Prasad S Adusumilli; Stephen F Stanziale; David P Eisenberg; Amit Bhargava; Teresa H Kim; Mei-Ki Chan; Rumana Huq; Mithat Gonen; Yuman Fong
Journal:  Int J Oncol       Date:  2006-06       Impact factor: 5.650

4.  Modelling the effect of GRP78 on anti-oestrogen sensitivity and resistance in breast cancer.

Authors:  Jignesh H Parmar; Katherine L Cook; Ayesha N Shajahan-Haq; Pamela A G Clarke; Iman Tavassoly; Robert Clarke; John J Tyson; William T Baumann
Journal:  Interface Focus       Date:  2013-08-06       Impact factor: 3.906

5.  Estrogens and insulin-like growth factor 1 modulate neoplastic cell growth in human cholangiocarcinoma.

Authors:  Domenico Alvaro; Barbara Barbaro; Antonio Franchitto; Paolo Onori; Shannon S Glaser; Gianfranco Alpini; Heather Francis; Luca Marucci; Paola Sterpetti; Stefano Ginanni-Corradini; Andrea Onetti Muda; David E Dostal; Adriano De Santis; Adolfo F Attili; Antonio Benedetti; Eugenio Gaudio
Journal:  Am J Pathol       Date:  2006-09       Impact factor: 4.307

6.  Trefoil factor 3 is oncogenic and mediates anti-estrogen resistance in human mammary carcinoma.

Authors:  Nagarajan Kannan; Jian Kang; Xiangjun Kong; Jianzhong Tang; Jo K Perry; Kumarasamypet M Mohankumar; Lance D Miller; Edison T Liu; Hichem C Mertani; Tao Zhu; Prudence M Grandison; Dong-Xu Liu; Peter E Lobie
Journal:  Neoplasia       Date:  2010-12       Impact factor: 5.715

7.  Induction of acquired resistance to antiestrogen by reversible mitochondrial DNA depletion in breast cancer cell line.

Authors:  Akihiro Naito; Jaime Carcel-Trullols; Cheng-hui Xie; Teresa T Evans; Takatsugu Mizumachi; Masahiro Higuchi
Journal:  Int J Cancer       Date:  2008-04-01       Impact factor: 7.396

8.  Morphological and functional features of hepatic cyst epithelium in autosomal dominant polycystic kidney disease.

Authors:  Domenico Alvaro; Paolo Onori; Gianfranco Alpini; Antonio Franchitto; Douglas M Jefferson; Alessia Torrice; Vincenzo Cardinale; Fabrizio Stefanelli; Maria Grazia Mancino; Mario Strazzabosco; Mario Angelico; Adolfo Attili; Eugenio Gaudio
Journal:  Am J Pathol       Date:  2008-01-17       Impact factor: 4.307

9.  Induction of apoptosis in human prostate stromal cells by 4-hydroxytamoxifen: an alternative therapy for benign prostate hyperplasia.

Authors:  Wolfgang Glienke; Yuliya Dolgova; Iris Müller; Sabine Grösch; Jochen Binder; Gerd Geisslinger; Dietger Jonas
Journal:  World J Urol       Date:  2004-09-23       Impact factor: 4.226

10.  Antiestrogen-resistant subclones of MCF-7 human breast cancer cells are derived from a common monoclonal drug-resistant progenitor.

Authors:  Kathryn R Coser; Ben S Wittner; Noël F Rosenthal; Sabrina C Collins; Antonia Melas; Shannon L Smith; Crystal J Mahoney; Keiko Shioda; Kurt J Isselbacher; Sridhar Ramaswamy; Toshi Shioda
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-25       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.